Department of Medicine, Division of Gastroenterology and Hepatology, Karolinska Institutet, Stockholm, Sweden.
APMIS. 2011 Jul;119(7):412-20. doi: 10.1111/j.1600-0463.2011.02746.x. Epub 2011 Apr 25.
Great progress has been made in understanding the development of non-alcoholic fatty liver disease (NAFLD) but less is known about the mechanisms underlying the progress from steatosis to steatohepatitis (NASH). Our aim was to evaluate if the amount and type of storage of fat in hepatocytes is of importance for hepatocyte injury. We also wanted to show if not only the innate immunity but also the adaptive immunity is involved in NASH. Thirty-one patients with NASH or borderline NASH and 18 non-NASH patients were investigated. Liver biopsies were scored for NASH according to Kleiner et al. Paraffin-embedded liver biopsies were stained with antibodies against CD3, TLR4, CD68, Cleaved Caspase-3, ICAM1, Foxp3 and ApopTag by immunohistochemistry. Serum soluble ICAM-1 (sICAM-1) were analysed by ELISA. The volume density of fat was 59% in the NASH patients and microvesicular fat, increased in high NAS score patients. ICAM-1 positive hepatocytes were seen in NASH patients and were localized in areas with microvesicular fat. Non-NASH biopsies were negative for ICAM-1 positive hepatocytes. The sICAM-1 were significantly higher in NASH-patients (339.8 ± 34.07) than in non-NASH patients (229.5 ± 12.14), p = 0.0015. Patients with NAS score over four had higher area of CD68 positive cells p = 0.0011 and Foxp3 positive cells (p = 0.024) than non-NASH patients. In liver tissue with NASH, hepatocytes with microvesicular steatosis seem to be expressing more inflammatory markers, and in this liver tissue an increased number of CD68 cells and regulatory T-cells (Tregs, e.g. Foxp3+ cells) were seen, indicating an involvement of, both the innate and the adaptive immunity.
非酒精性脂肪性肝病(NAFLD)的发病机制虽已有较大进展,但从单纯性脂肪变性发展至脂肪性肝炎(NASH)的具体机制仍知之甚少。本研究旨在评估肝细胞内脂肪的蓄积量和蓄积类型对肝细胞损伤的重要性,并探讨固有免疫和适应性免疫是否均参与 NASH 的发病机制。研究共纳入 31 例 NASH 或界线性 NASH 患者和 18 例非 NASH 患者,采用 Kleiner 评分标准对肝组织进行 NASH 评分,并通过免疫组织化学染色法检测石蜡包埋肝组织中 CD3、TLR4、CD68、Cleaved Caspase-3、ICAM1、Foxp3 和 ApopTag 的表达,通过 ELISA 法检测血清可溶性细胞间黏附分子-1(sICAM-1)的浓度。结果显示,NASH 患者肝组织中脂肪的体积密度为 59%,且高 NAS 评分患者的微泡性脂肪增加。NASH 患者肝组织中可见 ICAM-1 阳性的肝细胞,这些肝细胞定位于微泡性脂肪区域。非 NASH 患者的肝组织中未见 ICAM-1 阳性的肝细胞。NASH 患者的 sICAM-1 浓度显著高于非 NASH 患者(339.8±34.07),差异具有统计学意义(p=0.0015)。NAS 评分>4 分的患者肝组织中 CD68 阳性细胞和 Foxp3 阳性细胞的面积显著大于非 NASH 患者(p=0.0011 和 p=0.024)。NASH 患者肝组织中出现微泡性脂肪变性的肝细胞似乎表达更多的炎症标志物,且在这些肝组织中可见更多的 CD68 细胞和调节性 T 细胞(如 Foxp3+细胞),表明固有免疫和适应性免疫均参与了 NASH 的发病过程。